Abstract
To the Editor.— The neurotoxicity of the halogenated hydroxyquinolines was recently reviewed (225:395, 1973) following numerous reports linking subacute myelo-optic neuropathy (SMON) to iodochlorhydroxyquin. Optic atrophy without other neurologic involvement in two children followed treatment with diiodohydroxyquin (Diodoquin), a drug differing structurally by only one halogen atom. 1,2 A 3 1/2-year-old1 who had received 3,200 mg daily for two years for acrodermatitis enteropathica developed visual loss in the 20/200 range one month after increase of the dosage to 3,600 mg daily. Optic atrophy was noted; vision improved with lowering of the dose but worsened when it was raised. A 3 1/2-year-old 2 developed severe visual loss after eight weeks of 1,950 mg daily for nonspecific diarrhea, with evident optic atrophy on examination four weeks later and without improvement three years later. I have seen two similar cases of primary optic atrophy, otherwise unexplained, in children following treatment with diiodohydroxyquin. Case
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
